Addex Net Debt vs Common Stock Total Equity Analysis

ADXN Stock

USD 8.62 0.16 1.82%

Addex Therapeutics financial indicator trend analysis is way more than just evaluating Addex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Addex Therapeutics is a good investment. Please check the relationship between Addex Therapeutics Net Debt and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Net Debt vs Common Stock Total Equity

Net Debt vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Addex Therapeutics Net Debt account and Common Stock Total Equity. At this time, the significance of the direction appears to have no relationship.

The correlation between Addex Therapeutics' Net Debt and Common Stock Total Equity is 0.04. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Addex Therapeutics, assuming nothing else is changed. The correlation between historical values of Addex Therapeutics' Net Debt and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Addex Therapeutics are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Net Debt i.e., Addex Therapeutics' Net Debt and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Addex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Addex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.At this time, Addex Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 28th of November 2024, Enterprise Value Multiple is likely to grow to 0.01, while Selling General Administrative is likely to drop about 4.7 M.

Addex Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Non Current Liabilities Total	Net Receivables
Total Assets		-0.24	0.54	0.67	0.99	0.71	0.08	-0.99	0.57	0.58	0.99	0.54	0.08	0.99	-0.11	-0.34	0.77	-0.43	0.66	0.25	1.0	0.06	-0.19	0.31	0.37	0.45
Short Long Term Debt Total	-0.24		0.08	-0.08	-0.27	-0.42	0.13	0.23	-0.43	-0.46	-0.23	-0.19	0.25	-0.23	-0.04	-0.23	-0.23	0.51	0.03	-0.64	-0.23	-0.28	0.01	0.38	0.34	-0.33
Other Current Liab	0.54	0.08		0.87	0.47	0.79	-0.26	-0.46	0.28	0.0	0.46	0.81	0.52	0.46	-0.3	-0.3	0.83	-0.05	0.8	0.42	0.48	-0.18	-0.43	-0.11	0.26	0.66
Total Current Liabilities	0.67	-0.08	0.87		0.58	0.75	0.12	-0.61	0.17	0.42	0.61	0.66	0.26	0.61	0.07	-0.03	0.88	-0.03	0.97	0.54	0.63	0.25	-0.13	0.09	0.55	0.51
Total Stockholder Equity	0.99	-0.27	0.47	0.58		0.67	0.05	-0.99	0.61	0.56	0.99	0.51	0.05	0.99	-0.14	-0.36	0.71	-0.48	0.56	0.2	0.99	0.01	-0.2	0.3	0.29	0.43
Property Plant And Equipment Net	0.71	-0.42	0.79	0.75	0.67		-0.25	-0.63	0.7	0.22	0.62	0.9	0.38	0.62	-0.44	-0.39	0.89	-0.57	0.64	0.5	0.64	-0.13	-0.52	-0.22	0.07	0.78
Current Deferred Revenue	0.08	0.13	-0.26	0.12	0.05	-0.25		-0.14	-0.28	0.5	0.15	-0.44	-0.55	0.15	0.55	0.27	-0.04	0.2	0.26	-0.2	0.14	0.66	0.65	0.45	0.63	-0.51
Net Debt	-0.99	0.23	-0.46	-0.61	-0.99	-0.63	-0.14		-0.53	-0.6	-1.0	-0.44	0.02	-1.0	0.04	0.3	-0.71	0.4	-0.61	-0.2	-1.0	-0.09	0.11	-0.36	-0.37	-0.36
Retained Earnings	0.57	-0.43	0.28	0.17	0.61	0.7	-0.28	-0.53		0.14	0.53	0.64	0.29	0.53	-0.76	-0.74	0.48	-0.92	0.07	-0.01	0.53	-0.41	-0.66	-0.17	-0.28	0.59
Accounts Payable	0.58	-0.46	0.0	0.42	0.56	0.22	0.5	-0.6	0.14		0.61	0.01	-0.31	0.61	0.42	0.18	0.41	-0.2	0.47	0.4	0.61	0.69	0.31	0.46	0.46	0.03
Cash	0.99	-0.23	0.46	0.61	0.99	0.62	0.15	-1.0	0.53	0.61		0.43	-0.03	1.0	-0.03	-0.29	0.71	-0.4	0.61	0.21	1.0	0.11	-0.1	0.37	0.38	0.35
Non Current Assets Total	0.54	-0.19	0.81	0.66	0.51	0.9	-0.44	-0.44	0.64	0.01	0.43		0.75	0.43	-0.6	-0.5	0.75	-0.48	0.55	0.33	0.45	-0.35	-0.73	-0.29	0.0	0.84
Non Currrent Assets Other	0.08	0.25	0.52	0.26	0.05	0.38	-0.55	0.02	0.29	-0.31	-0.03	0.75		-0.03	-0.59	-0.46	0.24	-0.15	0.2	-0.05	-0.01	-0.53	-0.76	-0.27	-0.1	0.59
Cash And Short Term Investments	0.99	-0.23	0.46	0.61	0.99	0.62	0.15	-1.0	0.53	0.61	1.0	0.43	-0.03		-0.03	-0.29	0.71	-0.4	0.61	0.21	1.0	0.11	-0.1	0.37	0.38	0.35
Common Stock Total Equity	-0.11	-0.04	-0.3	0.07	-0.14	-0.44	0.55	0.04	-0.76	0.42	-0.03	-0.6	-0.59	-0.03		0.87	-0.19	0.64	0.17	0.29	-0.04	0.79	0.84	0.33	0.49	-0.54
Common Stock Shares Outstanding	-0.34	-0.23	-0.3	-0.03	-0.36	-0.39	0.27	0.3	-0.74	0.18	-0.29	-0.5	-0.46	-0.29	0.87		-0.3	0.58	0.0	0.42	-0.3	0.61	0.71	-0.09	0.16	-0.41
Other Current Assets	0.77	-0.23	0.83	0.88	0.71	0.89	-0.04	-0.71	0.48	0.41	0.71	0.75	0.24	0.71	-0.19	-0.3		-0.37	0.85	0.55	0.73	0.11	-0.3	0.18	0.42	0.6
Other Stockholder Equity	-0.43	0.51	-0.05	-0.03	-0.48	-0.57	0.2	0.4	-0.92	-0.2	-0.4	-0.48	-0.15	-0.4	0.64	0.58	-0.37		0.05	0.03	-0.4	0.3	0.54	0.1	0.26	-0.46
Total Liab	0.66	0.03	0.8	0.97	0.56	0.64	0.26	-0.61	0.07	0.47	0.61	0.55	0.2	0.61	0.17	0.0	0.85	0.05		0.46	0.63	0.36	-0.03	0.27	0.72	0.37
Property Plant And Equipment Gross	0.25	-0.64	0.42	0.54	0.2	0.5	-0.2	-0.2	-0.01	0.4	0.21	0.33	-0.05	0.21	0.29	0.42	0.55	0.03	0.46		0.22	0.43	0.1	-0.18	0.05	0.41
Total Current Assets	1.0	-0.23	0.48	0.63	0.99	0.64	0.14	-1.0	0.53	0.61	1.0	0.45	-0.01	1.0	-0.04	-0.3	0.73	-0.4	0.63	0.22		0.1	-0.11	0.36	0.39	0.37
Short Term Debt	0.06	-0.28	-0.18	0.25	0.01	-0.13	0.66	-0.09	-0.41	0.69	0.11	-0.35	-0.53	0.11	0.79	0.61	0.11	0.3	0.36	0.43	0.1		0.58	0.37	0.59	-0.36
Intangible Assets	-0.19	0.01	-0.43	-0.13	-0.2	-0.52	0.65	0.11	-0.66	0.31	-0.1	-0.73	-0.76	-0.1	0.84	0.71	-0.3	0.54	-0.03	0.1	-0.11	0.58		0.32	0.32	-0.59
Common Stock	0.31	0.38	-0.11	0.09	0.3	-0.22	0.45	-0.36	-0.17	0.46	0.37	-0.29	-0.27	0.37	0.33	-0.09	0.18	0.1	0.27	-0.18	0.36	0.37	0.32		0.72	-0.38
Non Current Liabilities Total	0.37	0.34	0.26	0.55	0.29	0.07	0.63	-0.37	-0.28	0.46	0.38	0.0	-0.1	0.38	0.49	0.16	0.42	0.26	0.72	0.05	0.39	0.59	0.32	0.72		-0.21
Net Receivables	0.45	-0.33	0.66	0.51	0.43	0.78	-0.51	-0.36	0.59	0.03	0.35	0.84	0.59	0.35	-0.54	-0.41	0.6	-0.46	0.37	0.41	0.37	-0.36	-0.59	-0.38	-0.21

Click cells to compare fundamentals

Addex Therapeutics Account Relationship Matchups

Addex Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	33.0M	20.2M	22.5M	8.3M	4.6M	4.4M
Other Current Liab	2.0M	1.3M	1.9M	1.6M	1.2M	1.2M
Total Current Liabilities	5.7M	3.6M	4.1M	3.3M	2.9M	4.0M
Total Stockholder Equity	25.5M	14.6M	16.9M	4.9M	1.1M	1.1M
Property Plant And Equipment Net	571.0K	633.1K	542.1K	398.7K	352.9K	335.3K
Current Deferred Revenue	212.7K	1.1M	820.1K	235.0K	270.2K	412.9K
Net Debt	(31.0M)	(18.1M)	(20.0M)	(6.6M)	(3.5M)	(3.7M)
Retained Earnings	(300.8M)	(313.7M)	(329.1M)	(349.9M)	(360.4M)	(378.4M)
Accounts Payable	2.2M	983.5K	1.8M	1.3M	984.4K	913.8K
Cash	31.5M	18.7M	20.5M	7.0M	3.9M	3.7M
Non Current Assets Total	639.9K	692.2K	600.0K	453.1K	407.3K	386.9K
Non Currrent Assets Other	68.9K	59.1K	57.9K	54.4K	54.3K	51.6K
Cash And Short Term Investments	31.6M	18.8M	20.5M	7.0M	3.9M	3.7M
Common Stock Shares Outstanding	26.4M	26.7M	34.1M	45.2M	74.3M	78.0M
Liabilities And Stockholders Equity	33.0M	20.2M	22.5M	8.3M	4.6M	4.4M
Other Current Assets	734.0K	661.2K	1.1M	270.4K	217.0K	206.2K
Other Stockholder Equity	286.4M	280.8M	272.3M	327.9M	329.9M	288.2M
Total Liab	7.5M	5.6M	5.6M	3.4M	3.5M	4.5M
Property Plant And Equipment Gross	571.0K	633.1K	4.3M	4.4M	4.7M	2.4M
Total Current Assets	32.4M	19.5M	21.9M	7.8M	4.2M	4.0M
Short Term Debt	373.0K	308.6K	287.7K	286.1K	274.0K	193.4K
Non Current Liabilities Total	1.8M	2.0M	1.5M	87.0K	603.1K	761.6K
Accumulated Other Comprehensive Income	7.1M	8.6M	24.4M	25.8M	29.8M	31.3M
Net Receivables	118.0K	68.4K	324.4K	598.3K	151.3K	271.7K
Other Liab	639.4K	1.6M	1.7M	1.3M	1.5M	813.2K
Net Tangible Assets	25.5M	14.6M	16.9M	4.9M	5.6M	5.4M
Other Assets	68.9K	59.1K	57.9K	54.4K	48.9K	66.0K
Short Term Investments	14.0K	64.9K	17.1K	3.2K	848.0	805.6
Property Plant Equipment	571.0K	633.1K	542.1K	398.7K	458.5K	275.1K
Net Invested Capital	25.5M	14.6M	16.9M	4.9M	1.1M	1.1M
Net Working Capital	26.7M	15.9M	17.8M	4.5M	1.3M	1.3M

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Addex Stock

0.49	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.39	NAMS	NewAmsterdam Pharma	Pair Corr
0.37	MNOV	MediciNova	Pair Corr

The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.

The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:

How To Invest In Addex

Details

Is Addex Stock a good investment?

Details

What is Addex Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(21.60)

Revenue Per Share

1.2

Quarterly Revenue Growth

(0.82)

Return On Assets

(0.62)

Return On Equity

(1.26)

The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Addex Net Debt vs Common Stock Total Equity Analysis

Net Debt vs Common Stock Total Equity

Net Debt vs Common Stock Total Equity Correlation Analysis

Correlation Coefficient

Net Debt

Common Stock Total Equity

Addex Therapeutics fundamental ratios Correlations

Addex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Addex Therapeutics fundamental ratios Accounts

Pair Trading with Addex Therapeutics

Moving against Addex Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Other Stockholder Equity	- 0.92	Retained Earnings